MNPR — Monopar Therapeutics
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1645469 ·
Last close
$85.24
Market Cap
$572.11M
52W High
$124.82
52W Low
$50.07
ADV30
160,007
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -6,644,663 | -5,313,300 | 134,978,829 | 52,757,766 | 4,123,859 |
| Mar 2026 | 0 | — | -5,225,253 | -3,893,050 | 137,983,725 | 52,544,263 | 2,589,313 |
| Dec 2025 | 0 | — | -6,155,228 | -5,200,795 | 140,717,709 | 61,833,552 | 2,890,156 |
| Sep 2025 | 0 | — | -4,093,075 | -3,437,601 | 144,197,278 | 127,677,360 | 2,639,430 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-10,011,881
Investing CF
$-68,710,838
Financing CF
$91,489,881
CapEx
—
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-1.67
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-93,402,580
Inventory
—
Receivables
—
ST Investments
$84,948,677
EBIT TTM
$-18,707,851
Pretax Income TTM
$-14,984,972
Interest Exp TTM
—
Analysts
13
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -16,704,415 | -13,716,894 | 140,717,709 | 2,890,156 | 137,827,553 | -12,201,291 |
| Dec 2024 | 0 | -16,161,721 | -15,586,419 | 60,291,071 | 5,254,300 | 55,036,771 | -6,404,139 |
| Dec 2023 | 0 | -8,831,235 | -8,402,196 | 7,345,159 | 1,757,393 | 5,587,766 | -7,858,293 |
| Dec 2022 | 0 | -10,536,877 | -10,515,638 | 13,226,954 | 3,137,302 | 10,089,652 | -7,228,559 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.92
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VREOF | Vireo Growth Inc. | $572.19M | $11.26 | — |
| SGMT | Sagimet Biosciences Inc. | $569.10M | $9.24 | — |
| NGNE | Neurogene Inc. | $566.52M | $28.31 | — |
| AQST | Aquestive Therapeutics, Inc. | $587.39M | $4.68 | — |
| CTMX | CytomX Therapeutics, Inc. | $588.33M | $2.70 | — |
News headlines (Yahoo Finance, 1h cache)
Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
2026-08-12 13:30 · Yahoo
Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease
2026-07-22 12:00 · Yahoo
Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team
2026-07-20 12:00 · Yahoo
Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease
2026-06-26 20:05 · Yahoo
Wall Street Analysts Believe Monopar Therapeutics (MNPR) Could Rally 88.92%: Here's is How to Trade
2026-06-15 13:55 · Yahoo
Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026
2026-06-01 11:00 · Yahoo
Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-05-14 18:00 · Yahoo
Monopar Therapeutics (NASDAQ:MNPR) Is In A Good Position To Deliver On Growth Plans
2026-05-03 13:26 · Yahoo
Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026
2026-04-19 23:00 · Yahoo
Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026
2026-08-19 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.